Insider Trading March 6, 2026

Delek US Director Executes $1.3M Sale Under 10b5-1 Plan as Shares Near 52-Week Peak

Zohar Shlomo disposes of 29,372 shares across March 4-5, 2026; company posts strong EPS but slightly below revenue expectations for Q4 2025

By Nina Shah DK
Delek US Director Executes $1.3M Sale Under 10b5-1 Plan as Shares Near 52-Week Peak
DK

Delek US Holdings director Zohar Shlomo sold 29,372 shares of the company's common stock under a pre-arranged 10b5-1 plan between March 4 and March 5, 2026, generating $1,303,382 in proceeds at prices between $43.00 and $45.50 per share. The transactions follow a year of significant share appreciation and come alongside the company's mixed fourth-quarter 2025 results, which featured a sizable adjusted EPS beat and a modest revenue shortfall.

Key Points

  • Director Zohar Shlomo sold 29,372 shares of Delek US between March 4 and March 5, 2026, under a pre-arranged 10b5-1 plan.
  • The sales generated $1,303,382 at prices from $43.00 to $45.50 per share; Shlomo now directly owns 18,989 shares.
  • Delek US reported a strong adjusted EPS beat for Q4 2025 ($2.31 vs. -$0.07 forecast) but missed revenue expectations ($2.43B vs. $2.55B).

Insider transactions

Director Zohar Shlomo of Delek US Holdings, Inc. (NYSE:DK) reported the sale of 29,372 shares of common stock in a Form 4 filing with the Securities and Exchange Commission. The dispositions occurred across two trading days - March 4 and March 5, 2026 - and were carried out pursuant to a previously established 10b5-1 trading plan.

Transaction breakdown

The aggregate proceeds from the sales totaled $1,303,382, with execution prices ranging from $43.00 to $45.50 per share. On March 4, Shlomo sold 7,343 shares at $43.00. On March 5, he completed three separate transactions, each for 7,343 shares, at prices of $44.00, $45.00 and $45.50 respectively, accounting for the remaining 22,029 shares sold over that day.

Post-sale holdings and plan details

Following these transactions, Shlomo is recorded as directly owning 18,989 shares of Delek US Holdings. The trades were executed under a 10b5-1 plan that was adopted on November 13, 2025.

Share-price context

The insider sales take place against a backdrop of significant appreciation in Delek US stock. Over the past 12 months the shares have advanced 209%, and the stock is trading close to its 52-week high of $45.74. An InvestingPro analysis cited in the filing materials indicates that, at current levels, the stock appears overvalued relative to its Fair Value. The analysis also notes that deeper research on DK and more than 1,400 other U.S. stocks is available via InvestingPro’s Pro Research Report.

Recent financial results

Separately, Delek US reported fourth-quarter 2025 results that offered a mixed picture. The company posted an adjusted earnings per share of $2.31, versus a forecast of -$0.07, representing a 3,400% positive surprise relative to consensus expectations. Revenue for the quarter was $2.43 billion, compared with an anticipated $2.55 billion, producing a 4.71% negative surprise. The combination of a strong EPS outperformance and a revenue shortfall highlights a divergence between profitability measures and top-line momentum in the quarter.

What this means for observers

The Form 4 filing confirms the director sale was pre-arranged under a 10b5-1 plan adopted in late 2025 and provides precise transaction details and ownership levels after the trades. Investors and analysts monitoring insider activity, valuation metrics and the company’s recent earnings cadence may weigh these data points as they evaluate DK’s near-term outlook.


Note: All transaction sizes, prices, dates and company results reported here are taken from the cited Form 4 filing and the company’s reported fourth-quarter 2025 results.

Risks

  • Stock valuation risk - InvestingPro analysis indicates the shares appear overvalued relative to Fair Value, which could affect investor sentiment and market valuation.
  • Revenue shortfall - The Q4 2025 revenue miss versus expectations highlights potential top-line weakness that may influence future earnings outlooks.
  • Insider selling perception - While executed under a 10b5-1 plan, the director’s sale may be viewed by some market participants as a signal, which can impact trading dynamics in the energy and specialty finance sectors.

More from Insider Trading

Ligand CFO Disposes $2.76M in Stock as Shares Trade Near 52-Week High Mar 7, 2026 Ligand Chief Legal Officer Sells About $1.03 Million in Shares, Exercises Options Mar 7, 2026 Energy Recovery SVP Disposes $218,308 in Shares as Stock Nears Yearly Low Mar 7, 2026 Matson Commercial Chief Disposes $1.43M in Shares Amid Recent Earnings Beat Mar 7, 2026 Madrigal Pharmaceuticals CFO Executes $854K Stock Sale Amid Option Grant and Zero‑Value Share Award Mar 7, 2026